发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Certolizumab pegol in the treatment of axial spondyloarthritis. 赛妥珠单抗 pegol 用于治疗轴性脊柱关节炎。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-26 DOI: 10.2217/imt-2023-0225
Elizabeth Anderson, Secia Beier, Julianna Desmarais
{"title":"Certolizumab pegol in the treatment of axial spondyloarthritis.","authors":"Elizabeth Anderson, Secia Beier, Julianna Desmarais","doi":"10.2217/imt-2023-0225","DOIUrl":"https://doi.org/10.2217/imt-2023-0225","url":null,"abstract":"<p><p>Axial spondyloarthritis is a chronic, immune-mediated systemic inflammatory disease encompassing ankylosing spondylitis and nonradiographic axial spondyloarthritis. TNF inhibitors are the preferred second line therapy for patients with active axial spondyloarthritis. Certolizumab pegol is a TNF inhibitor approved for treatment of both. Three large phase III trials (RAPID-axSpA, C-axSpAnd and C-OPTIMISE) and one large phase IV trial (CIMAX) establish its clinical efficacy in treatment of active disease and maintenance of remission for both diseases. Real world evidence demonstrates clinical efficacy and benefits including reduced bone loss, reduced risk of uveitis, safety in pregnancy and lactation and index drug survival of 10 years. It is generally well tolerated, though can be associated with increased risk of serious infections.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review. 辛替利马引发的严重糜烂性出血性胃炎和幽门梗阻：病例报告和文献综述。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-26 DOI: 10.2217/imt-2023-0325
Wenfang Xiong, Zhenzhen Yang, Youxiang Chen
{"title":"Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.","authors":"Wenfang Xiong, Zhenzhen Yang, Youxiang Chen","doi":"10.2217/imt-2023-0325","DOIUrl":"https://doi.org/10.2217/imt-2023-0325","url":null,"abstract":"<p><p>Immune checkpoint inhibitors could restore immune surveillance to attack tumor through targeting CTLA-4, PD-1 or PD-L1, and have achieved huge success. However, immune-related adverse events (irAEs) have been attracting attention as their application is expanding. Gastritis is relatively rare as a subtype of irAEs, particularly severe gastritis. Guidelines on its clinical management still remain undefined due to limited data. Sintilimab is a PD-1 inhibitor approved in China. Here we offer a case of sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction. Conventional proton pump inhibitors and mucosal protective agents did not take effect, so glucocorticoid was chosen. This severe gastritis was successfully cured finally. Our report describing its clinical performances, endoscopic characteristics and treatments, could assist clinicians to better know this rare irAE.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma. 使用屋尘螨提取物的过敏原免疫疗法对小儿支气管哮喘的疗效。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-26 DOI: 10.2217/imt-2024-0024
Masaaki Hamada, Keigo Saeki, Ichiro Tanaka
{"title":"Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma.","authors":"Masaaki Hamada, Keigo Saeki, Ichiro Tanaka","doi":"10.2217/imt-2024-0024","DOIUrl":"https://doi.org/10.2217/imt-2024-0024","url":null,"abstract":"<p><p><b>Aim:</b> We compared the effectiveness of rush subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) using standardized house dust mite (HDM) extract for pediatric bronchial asthma (BA). <b>Methods:</b> We followed the pediatric BA treatment score during 3 years of treatment. We assessed the median time to no longer requiring long-term control pharmacotherapy (LTCP) for BA (LTCP-free). We compared the outcomes after adjustment for confounding factors and propensity score matching. <b>Results:</b> Patients in the HDM SCIT group achieved the LTCP-free status significantly earlier than those in the HDM SLIT group after adjustment for confounding factors and propensity score matching. <b>Conclusion:</b> Patients treated for pediatric BA with rush HDM SCIT had earlier onset of therapeutic effects than those with HDM SLIT.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158. 彭博利珠单抗在中国微卫星不稳定性高/错配修复缺陷肿瘤患者中的应用KEYNOTE-158。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-20 DOI: 10.2217/imt-2023-0294
Jianming Xu, Yimin Mao, Nong Xu, Yuxian Bai, Dong Wang, Xiaojun Chen, Xianli Yin, Yanhong Deng, Jianwei Yang, Jieqing Zhang, Jie Tang, Yi Huang, Jiayi Li, Suxia Luo, Hong Zheng, Weidong Zhao, Miaomiao Xu, Nan Li, Yixiang Mao, Alexander Gozman, Xiaohua Wu
{"title":"Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158.","authors":"Jianming Xu, Yimin Mao, Nong Xu, Yuxian Bai, Dong Wang, Xiaojun Chen, Xianli Yin, Yanhong Deng, Jianwei Yang, Jieqing Zhang, Jie Tang, Yi Huang, Jiayi Li, Suxia Luo, Hong Zheng, Weidong Zhao, Miaomiao Xu, Nan Li, Yixiang Mao, Alexander Gozman, Xiaohua Wu","doi":"10.2217/imt-2023-0294","DOIUrl":"https://doi.org/10.2217/imt-2023-0294","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate pembrolizumab in patients of Chinese descent with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors enrolled in KEYNOTE-158 (Cohort L). <b>Methods:</b> Patients with MSI-H/dMMR advanced tumors received pembrolizumab 200 mg IV Q3W. Primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS) and overall survival (OS). <b>Results:</b> 24 patients were enrolled (20 were evaluable for efficacy). With median follow-up of 12.4 months, the ORR was 70%. DOR, PFS and OS were all not reached. A total of 19 (79%) patients had a treatment-related adverse event (AE; grade ≥3 in 4 [17%]), and 8 (33%) had an immune-mediated AE (grade ≥3 in (4 [17%]). <b>Conclusion:</b> Pembrolizumab provided meaningful and durable responses with manageable safety. These results are consistent with those reported for the global trial.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BATF-mediated regulation of exhausted CD8+ T-cell responses and potential implications for chimeric antigen receptor-T therapy. BATF 介导的 CD8+ T 细胞衰竭反应调控以及对嵌合抗原受体-T 疗法的潜在影响。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-24 DOI: 10.2217/imt-2023-0170
Chao Sun, Dan Li, Zhengxin Wang
{"title":"<i>BATF</i>-mediated regulation of exhausted CD8<sup>+</sup> T-cell responses and potential implications for chimeric antigen receptor-T therapy.","authors":"Chao Sun, Dan Li, Zhengxin Wang","doi":"10.2217/imt-2023-0170","DOIUrl":"10.2217/imt-2023-0170","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy for malignant tumors has reached a crucial stage, with recent studies underscoring the role of T-cell exhaustion in determining the efficacy of CAR-T therapy. This trailblazing discovery has opened new avenues to augment the potency of CAR-T therapy. Basic leucine zipper ATF-like transcription factor (<i>BATF</i>) is indispensable in alleviating T-cell exhaustion and is pivotal in the early stages of CD8<sup>+</sup> T-cell differentiation. In cooperation with other transcription factors, it plays a key role in the differentiation and maturation processes of exhausted T cells. A deeper comprehension of <i>BATF</i>'s mechanisms in T-cell biology may yield novel insights into amplifying the efficacy of CAR-T therapy.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"331-340"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peripheral B-cell levels predict efficacy and overall survival in advanced melanoma patients under PD-1 immunotherapy. 外周 B 细胞水平可预测接受 PD-1 免疫疗法的晚期黑色素瘤患者的疗效和总生存期。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2023-12-21 DOI: 10.2217/imt-2023-0105
Xiaoli Liu, Shuochuan Liu, Zhiqiang Jiang, Chengliang Yang, Xuchu Yang, Jia Li, Huaimin Liu
{"title":"Peripheral B-cell levels predict efficacy and overall survival in advanced melanoma patients under PD-1 immunotherapy.","authors":"Xiaoli Liu, Shuochuan Liu, Zhiqiang Jiang, Chengliang Yang, Xuchu Yang, Jia Li, Huaimin Liu","doi":"10.2217/imt-2023-0105","DOIUrl":"10.2217/imt-2023-0105","url":null,"abstract":"<p><p><b>Aims:</b> Programmed death-1 (PD-1) blockade is a vital therapy for solid tumors, but not all patients benefit. Identifying which patients will benefit from immunotherapy is a key focus in oncology research. <b>Patients & Methods:</b> This study analyzed the correlation between the number of peripheral lymphocytes and the efficacy and prognosis of immunotherapy in advanced malignant melanoma. <b>Results:</b> Patients with a partial response had significantly lower peripheral B cell levels, and patients with a lower number of B lymphocytes had a longer survival time. <b>Conclusion:</b> These results suggest that peripheral B cells are correlated with the efficacy of PD-1 antibody and prognosis and are thus potential biomarkers for the efficacy and prognosis of PD-1 antibody immunotherapy in malignant melanoma.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"223-234"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatment. 揭开癌症治疗中的致癌驱动因素与免疫疗法疗效之间的联系。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0190
Hiba Mechahougui, Alex Friedlaender
{"title":"Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatment.","authors":"Hiba Mechahougui, Alex Friedlaender","doi":"10.2217/imt-2023-0190","DOIUrl":"10.2217/imt-2023-0190","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"267-271"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathological findings directing immunotherapy in renal cell carcinomas. 引导肾细胞癌免疫疗法的病理学发现。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI: 10.2217/imt-2023-0249
Fadime Eda Gökalp Satıcı, Yasemin Yuyucu Karabulut
{"title":"Pathological findings directing immunotherapy in renal cell carcinomas.","authors":"Fadime Eda Gökalp Satıcı, Yasemin Yuyucu Karabulut","doi":"10.2217/imt-2023-0249","DOIUrl":"10.2217/imt-2023-0249","url":null,"abstract":"<p><p>Tweetable abstract Immunotherapy options in RCC treatment are increasing day by day. In pursuit of this objective, we have explored the role of pathology throughout the process, from the development to the implementation of immunotherapy in this paper.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"199-204"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment. 摘要：银屑病中的赛妥珠单抗 pegol，包括结构特点、药代动力学和治疗。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-02-06 DOI: 10.2217/imt-2023-0058
Michio Tokuyama, Tomotaka Mabuchi
{"title":"Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment.","authors":"Michio Tokuyama, Tomotaka Mabuchi","doi":"10.2217/imt-2023-0058","DOIUrl":"10.2217/imt-2023-0058","url":null,"abstract":"<p><p>Psoriasis pathogenesis involves TNF-α, IL-23 and IL17, against which biologics have been highly effective. Among the five TNF-α inhibitors available for psoriasis, namely infliximab, adalimumab, etanercept, golimumab and certolizumab pegol (CZP), CZP has a unique mechanism of action due to its structure. As CZP lacks the Fc region, it does not cross the placenta and can be safely used in pregnant women. Its PEGylated nature allows for longer distribution time in tissues, potentially leading to a longer-lasting effect compared with other TNF-α inhibitors. In clinical trials, the efficacy of CZP on psoriasis skin symptoms and joint symptoms was comparable to other TNF-α inhibitors, with no discernible differences in safety profiles.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"273-285"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events. 评估夏尔森综合症指数在预测免疫检查点抑制剂相关不良事件方面的有效性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-30 DOI: 10.2217/imt-2023-0270
İlknur Deliktaş Onur, Emel Mutlu, Elif Sertesen, Tuğba Önder, Ayşe Ocak Duran, Mevlüde İnanç
{"title":"Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events.","authors":"İlknur Deliktaş Onur, Emel Mutlu, Elif Sertesen, Tuğba Önder, Ayşe Ocak Duran, Mevlüde İnanç","doi":"10.2217/imt-2023-0270","DOIUrl":"10.2217/imt-2023-0270","url":null,"abstract":"<p><p><b>Aims:</b> Our study aimed to evaluate the effectiveness of the Charlson Comorbidity Index (CCI) in predicting immune-related adverse events (irAEs) in solid tumor patients receiving immunotherapy. <b>Patients & methods/materials:</b> The CCI score at the time of initiation of immunotherapy was calculated in 164 solid tumor patients receiving immunotherapy and the correlation between the CCI score and immune toxicity was evaluated. <b>Results:</b> A significant relationship was found between CCI score and irAEs in lung cancer and renal cell cancer patients. In malignant melanoma, no significant relationship was found between the CCI score and the occurrence of irAEs. <b>Conclusion:</b> We argue that CCI can be used to predict irAEs, but we believe that a specific comorbidity index that includes autoimmune diseases should be developed.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"295-303"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信